Central Drugs Standard Control Organization

Directorate General of Health Services
Ministry of Health & Family Welfare
Government of India

Circulars

S.no Title Release Date Download Pdf Pdf Size
1 Shifting of CDSCO Sub Zonal office from AIIMS Department of Pharmacology Level 4 A5 Block Medical College Virbhadra Road Rishikesh Uttrakhand 2025-Jan-06 648 KB
2 Submission information of Immovable Property Return for the year 2024 through SPARROW Portal in r/o all employee of CDSCO (HQ), Zone, Sub-Zone, Lab and Ports offices 2024-Dec-23 224 KB
3 Circular dated 09.12.2024 for the Shipment from foreign NRAs to India 2024-Dec-09 433 KB
4 Circular dated 12.11.2024 Round Table meeting with the Stakeholders regarding Regulation of Cosmetics 2024-Nov-12 236 KB
5 Reminder- Calculation of Income Tax Savings for the F.Y 24-25 2024-Nov-12 292 KB
6 Circular regarding calculation of Income Tax for the Financial Year 2024-25 2024-Sep-30 628 KB
7 Circulars dated 11.09.2024 2024-Sep-11 85 KB
8 Draft Guidelines on Good Distribution Practices for Pharmaceutical Products 2024-Aug-09 3609 KB
9 E-Governance Circular dated 09.08.2024 2024-Aug-09 44 KB
10 Implementation of Schedule M and WHO Technical Report Series 2024-Aug-07 845 KB
11 Income Tax Circular regarding Tax regime and Savings dated 31..07.2024 2024-Jul-31 339 KB
12 Circular regarding Requirement of Toxicity Studies for New Drugs SNDs and FDCs 2024-Jul-29 379 KB
13 Circular regarding The Blood Centre situated in Hospital based or Hospital Campus 2024-May-22 441 KB
14 Appointment of CPIO and ACPIO (Nodal Officer) for the purpose of RTI Matters 2024-May-17 33 KB
15 Circular 16.05.2024 Digital Signature Certificate DSC is being used by CDSCO for signing the various online forms issuing NOCs through various online portals and digitally transmitted documents 2024-May-16 85 KB
16 Circular Regulation of all Class C & D Medical Devices under Licensing regime w.e.f 01.10.2023, as per G.S.R. 102(E) dt 11.02.2020 2024-May-16 403 KB
17 Circular on Medical Device related Adverse Events reporting by Medical Device Licence Holder under Materiovigilance Programme of India 2024-May-15 106 KB
18 Circular-Retention of license or certificates under Medical Devices Rules, 2017 2024-May-15 207 KB
19 Transfer order of CDSCO 2024 2024-May-14 1463 KB
20 Office Memorandum dated 12.04.2024 Grievance Redressal Officer for redressing the grievances of Persons with Disabilities under Section 23 of RPWD Act 2016 for CDSCO 2024-Apr-12 186 KB
21 Circular Guidelines for risk based inspections of manufacturing facilities 2024-Mar-27 2755 KB
22 Circular regarding submission of PSUR of Medical devices/ IVD through Medical Devices Portal 2024-Mar-19 475 KB
23 Office memorandum regarding to provide information in respect of reporting/reviewing officers for creation workflow and generating APAR 2024-Mar-15 292 KB
24 Circular regarding subbission of online applications of PSURs MA of New Drugs SNDs FDCs Biologicals Veterinary 2024-Feb-26 263 KB
25 Circular Details of Cosmetics lmported by the Applicant Annually as per the Conditions of lmport Registration Number in Form Cos-4A under the Cosmetics Rules 2020 2024-Feb-23 304 KB
26 Corrigendum dated 13 Feb 2024 2024-Feb-13 90 KB
27 Regulatory guidelines for sampling of drugs cosmetics and medical devices by Drugs Inspectors of Central and State Drug Authorities 2024-Feb-09 1016 KB
28 Income Tax savings for FY- 2023-2024 2024-Feb-05 240 KB
29 Office Order regarding senitization programme on PoSH (Prevention of Sexual Harassment) 2024-Jan-16 1033 KB
30 Submission of Information of Immovable Property Return for the year 2023 through e-HRMS 2.0 in respect of all employees of CDSCO(HQ) Zone Sub-Zone Lab and Port Offices 2024-Jan-03 406 KB
31 Submission information of Immovable Property Return for the year 2023 in respect of Group-A & Group-B Gazetted and Group-B & Group-C Non-Gazetted (Ministerial and Non-Ministerial) Officers of CDSCO HQ and Zone Sub-Zone Lab and Ports Offices 2023-Dec-19 787 KB
32 Participation in National Programme for Civil Services Capacity Building (NPCSCB) Mission Karmayogi launched by the Government to promote role based capacity building of Civil Servants with the goal of offering a wide range of learning resources n the IGOT Karmayogi platform to enhance the knowledge skills and attitude of officials 2023-Dec-13 427 KB
33 Hospitality facility in respect of the officers of CDSCO Directorate General of Health Services 2023-Dec-07 388 KB
34 Participation in National Programme for Civil Services Capacity Building (NPCSCB) – Mission Karmayogi launched by the Government to promote role based capacity building of Civil Servants with the goal of offering a wide range of learning resources n the IGOT Karmayogi platform to enhance the knowledge skills and attitude of officials 2023-Nov-22 3069 KB
35 Circular Regarding Implement e-HRMS 2.0 Portal dated 16.11.2023 2023-Nov-16 259 KB
36 Corrigendum to Notice inviting Expression of Interest for development of Digital Drugs Regulatory System 2023-Nov-10 434 KB
37 Circular regarding online applicatioin for Post Approval Changes (PAC) w.r.t Marketing Authorization (MA) for Human Vaccines and Anti-sera 2023-Nov-10 678 KB
38 Circular for PAC Online Applications for Clinical Trial of Vaccine 2023-Oct-26
39 Reconstitution of Internal Complaint Committee on Sexual Harassment HQ 2023-Oct-18 459 KB
40 Regulation of all Class C & D Medical Devices Under Licensing regime, w.e,f 01.10.2023 as per GSR102E dated 11.02.2020 2023-Oct-12 385 KB
41 Reconstitution of Internal Complaint Committee on Sexual Harassment Mumbai West Zone 2023-Oct-09 178 KB
42 Reconstitution of Internal Complaint Committee on Sexual Harassment 2023-Sep-29 124 KB
43 Hon'ble Supreme Court in Civil Apeal NO. 2482 of 2014 forwarded by Ministry of Health and Family Welfare, an Internal Complaints Committee (ICC) as per provision of PoSH Act has already been formed by CDSCO(HQ) 2023-Sep-20 80808 KB
44 Request for furnishing the details for timely generation of APARs on Sparrow portal through e-mail at apar.cdsco@gmail.com 2023-Sep-20 302 kb
45 Approval of NABL Accredited Private Testing Laboratory for Testing of Cough Syrup to be exported by the Manufacturer/Exporter 2023-Sep-13 2263 KB
46 Calculation of lncome Tax for the Financial Year 2O23-24 2023-Sep-11 392 KB
47 Reconstitution of Internal Complaint Committee on Sexual Harassment Hyderabad 2023-Sep-04 77 KB
48 Reconstitution of Internal Complaint Committee on Sexual Harassment Chennai 2023-Sep-04 57 KB
49 Reconstitution of Internal Complaint Committee on Sexual Harassment CDTL Chennai 2023-Sep-04 41 KB
50 Reconstitution of Internal Complaint Committee on Sexual Harassment CDTL Hyderabad 2023-Sep-04 396 KB
51 Reconstitution of Internal Complaint Committee on Sexual Harassment CDTL Kasauli 2023-Sep-04 591 KB
52 Reconstitution of Internal Complaint Committee on Sexual Harassment CDTL Kolkata 2023-Sep-04 248 KB
53 Reconstitution of Internal Complaint Committee on Sexual Harassment CDTL Mumbai 2023-Sep-04 318 KB
54 Reconstitution of Internal Complaint Committee on Sexual Harassment North Zone 2023-Sep-04 160 KB
55 Azadi Ka Amrit Mahotsav AKAM HarGhar Tiranga Campaign 2023-Aug-11 10055 KB
56 Office Memorandam regarding appoint of CPIO for the purpose of RTI Technical matter 2023-Aug-01 313 KB
57 Online Application for the issuance of Form 11 (Test License) for Veterinary Vaccines /Drugs 2023-Jul-20 286 KB
58 Reconstitution of Internal Complaint Committee on Sexual Harassment dated 18.07.2023 2023-Jul-18 423 KB
59 Transfer Policy for the officers/officials of CDSCO dated 03.07.2023 2023-Jul-03 69 KB
60 Transfer order of DDC(I) dated 14.06.2023 2023-Jun-14 1066 KB
61 Daily Updation of No. of Batches of Cough syrup sample for Export at Different Laboratories for testing 2023-Jun-13 1224 KB
62 Circular for Licensing of Class C D medical devices 2023-Apr-12 310 KB
63 Rotational Tansfer of Officers of CDSCO 2023-Mar-21 247 KB
64 Office Memorandum regarding RTI Act 2005 for RDTL Chandigarh 2023-Mar-16 308 KB
65 Circular regarding submission of Immovable property Return for the year of 2022 2022-Dec-21 630 KB
66 Information Document on Prevention of Sexual Harassment of Women at Workplace 2022-Nov-04 478 KB
67 Information Document on Suspension 2022-Nov-04 430 KB
68 Circular regarding information document on pay fixation issued by Department of personnel and Training 2022-Sep-13 684 KB
69 Circular regarding Information document on increment issued by Department of personnel and Training 2022-Sep-12 624 KB
70 Transfer order for the year 2022-2023-4 2022-Sep-08 10353 KB
71 Har Ghar Tiranga Campaign 2022-Jul-13 812 KB
72 Transfer order for the year 2022-2023-2 2022-Jul-05 4607 KB
73 Office Memorandum regarding Sexual Harassment of Women at work Place constitution of a complaints committee 2022-Jun-17 856 KB
74 Modification of Instructions regarding Booking of Air Tickets on Government account 2022-Jun-16 1453 KB
75 Transfer order for the year 2022-2023 2022-May-04 4429 KB
76 Transfer order for the year 2022-2023-1 2022-Mar-10 1334 KB
77 Circular regarding filling up for the post of Junior Scientific Assistant CDTL Mumbai 2022-Jan-12 5011 KB
78 Circular regarding attendance dated 7 Jan 2022 2022-Jan-07 116 KB
79 Circulars dated 27 Oct 2021 regarding 2021-Oct-27 901 KB
80 Prior approval for Global Tender Enquiry under rule 161(Vi) of General Financial Rules (GFRs) 2021-Oct-14 1338 KB
81 Office Order regarding the Leaves(s) in respect of the officers of CDSCO 2021-Oct-12 432 KB
82 Office order regarding leaves granted to Officers of CDSCO 2021-Aug-19 930 KB
83 Circular regarding Azadi Ka Amrit Mahotsav 2021-Aug-12 2039 KB
84 Circular regarding attending office during Parliament Session 2021-Aug-03 1880 KB
85 Data for Income Tax Calculation for the Financial Year 2021-22 2021-Aug-02 3990 KB
86 Clarification if change in a) Polymorphs/crystalline/amorphous/solvates/hydrate etc (b) salt and (c) Derivative/analogue/ester etc of already approved active substance to be considered as new drug if main active moiety (Active Pharmaceutical Ingredient-API) is same? 2021-Jul-23 131 KB
87 Consolidated Instructions for Global Tender Enquiry (GTE) under Rule 161(iv) of General Financial Rules (GFRs), 2017 2021-Jul-07 3372 KB
88 Circular regarding attending office regularly dated 07.07.2021 2021-Jul-07 602 KB
89 Reconstituting of Internal Complaint Committee on sexual Harassment cases regarding 25 june 2021 2021-Jun-25 920 KB
90 Special Condition under which the permission for import of drug with residual shelf life less than 60% is allowed 2021-Apr-13 373 KB
91 RT-PCR Test for COVID-19 of the staff of CDSCO at FDA bhawan 2021-Apr-07 908 KB
92 Declaration of Holiday on 14th April 2021 Dr. B R Ambedkar 2021-Mar-31 334 KB
93 Office Meorandum regarding for pusuing higher qualification 2021-Mar-26 735 KB
94 Office Memorandum regarding submission of immovable property retrun for the year 2020 2021-Jan-05 1811 KB
95 Special condition under which the permission for import of drug with residual shelf life less than 60% is allowed 2020-Dec-18 983 KB
96 Circulars dated 18 December 2020 2020-Dec-18 520 KB
97 Clarification regarding admissibility of Transport allowance druing Nation-Wide Lockdown due to COVID-19 pandemic 2020-Dec-08 328 KB
98 Clarification regarding reference standards 2020-Dec-04 260 KB
99 Submmission on Leave application in i-connect leave management System 2020-Oct-07 493 KB
100 circular regarding Special Condition under which the permission for import of drug with residual shelf life less than 60 % is allowed 2020-Jul-10 212 KB
101 Circular regarding Extension of validity of BA/BE Study Centres regarding 2020-Apr-30 344 KB
102 Circular regarding pocdure for lot release of Human vaccine in view of prevailing COVID-19 pandemic 2020-Apr-03 454 KB
103 Circular regarding exemption of biometric machine attendance till 31.03.2020 2020-Mar-06 857 KB
104 Circular regarding disposal of the application of WC for active substances exported to the Eu for medicinal products for Human use in accordance with Acrticle 42(2) 2020-Mar-04 664 KB
105 Circular regarding Disposal of the application of WHO-GMP 2020-Mar-03 617 KB
106 Circular Submission of certifice copy of APAR for consideration for Promotion confirmation grant of MACP etc to CDSCO HQ 2020-Feb-17 116 KB
107 Circular regarding Rational use of Antibiotics for limiting Antimicrobial resistance 2019-Dec-23 766 KB
108 Information/Guidance regarding uploading of manufacturing site and formulations data on SUGAM Portal 2019-Nov-29 384KB
109 Circular regarding clarification on stability data requirement in case of Clinical Trial and Bioavailability-Bioequivalance study 2019-Oct-18 668 KB
110 Clarification on stability data requirement in case of CT and BABE study 2019-Oct-18 516 KB
111 Circular regarding procedure for booking of air-tickets on LTC 2019-Sep-30 235 KB
112 Circulard dated 11 September 2019 2019-Sep-11 53 KB
113 Circular regarding WC dated 9.9.2019 2019-Sep-09 755 KB
114 Clarification on manufacturing of new drug by a manufacturer in their own multiple manufactring site 2019-Aug-30 89 KB
115 NOC for manufacture of Unapproved Banned New Drugs solely for Export purpose 2019-Aug-05 425 KB
116 Disposal of unserviceable/obsolete item of CDSCO 2018-Dec-21 322 KB
117 Pending Annual Performance Appraisal Report APARs of Drugs Inspectors in CDSCO regarding 2018-Sep-27 735 KB
118 Creation of Veterinary cell at CDSCO(HQ), New Delhi 2018-Jul-03 388KB
119 Gazette Notification of Drug Inspector 2018-Apr-12 1,680lb
120 Additional information regarding Medical Devices Rules 2017 2018-Mar-16 1,230kb
121 NSQ Vi-Conjugate Typhoid Vaccine Batch No.TC010915 and Batch No. TC010417 of M/s Bio Med Pvt Ltd 2018-Mar-14 904kb
122 Request to advice the manufacturers to submit stability data of non patent and proprietary medicines for grant of permission 2017-Aug-18 274kb
123 Circular Establishment of facilities for ther activities of coating assembling of components, sterilization etc for devices 2017-Aug-09 562kb
124 Clarification regarding submission of application for post approval changes of human Vaccines 2017-Jul-18 302kb
125 Testing of Sample of Imported Vaccine 2017-Jun-05 1,420kb
126 Acknowledgement for Level-III post approval changes Annual Notifications of biological products (vaccines &r-DNA) 2017-May-26 485kb
127 Delegation of Power to Sign Licence and Rigistration 2017-Apr-13 2920kb
128 Merit List based on the written examination held on 09.04.2017 at NIB Noida for WHO Roational Fellowhip Selection 2017-Apr-10 3,500kb
129 Circular regarding Human Vaccine 2017-Feb-16 50kb
130 Circular regarding first time import/manufacture in the country of Active Pharmaceutical Ingredient API of a drug which has earlier been approved as New Drug in Finished Formulation for import and marketing and /or allowed for import under import registration and Licensing 2016-Dec-30 396kb
131 Circular regarding NOC for export of biological products (Vaccine and r-DNA products) under Form 29 license to manufacture drugs for purposes of examination, test or analysis 2016-Dec-13 237kb
132 Circular regarding extension of Shelf Life within or up to the period of 60 Months for export purpose 2016-Oct-27 309kb
133 Circular regarding requirement of approval of Review Committee on Genetic Manipulation under Department of Biotechnology for r-DNA 2016-Aug-30 487kb
134 Circular regarding Requirement of NOC from DCGI for addition of new Clinical trial site or investigator 2016-Aug-03 493kb
135 Circular regarding Restriction of conducting three clinical trials per investigator 2016-Aug-02 243kb
136 Circular regarding Requirement of 50 bedded site for clinical trial 2016-Aug-02 258kb
137 Manufacturing and Marketing of Unapproval Drug, VitaminK2-7 2016-Jan-01 39kb
138 Pre-Screening work 2015-Dec-30 244kb
139 Requirement of approval of Review Committee on Generic Manipulation (RCGM) under Department of Biotechnology for r-DNA derived drugs like Insulin, Monoclonal antibody, etc 2015-Nov-10 242kb
140 Circular to all State/UT's Drugs Controller 2015-Aug-06 46kb
141 Draft Senority List of Assistant Drugs Inspectors CDSCO 2015-Jul-13 752kb
142 Draft Senority List of Drugs Inspectors CDSCO 2015-Jul-01 3,240kb
143 Circular regarding Import of Cosmetics 2015-Jun-29 428kb
144 2015-Jun-17 337kb
145 Availability of H1N1 Vaccine 2015-Feb-17 48kb
146 Exemption of Veterinary products from the purview of DCG(I) Letter 2015-Jan-15 361KB
147 Circular regarding written confirmation certificate 2014-Oct-22 92kb
148 Circular regarding strict regulatory control over the manufacture,sale and distribution of Oxytocin 2014-Oct-22 897kb
149 Circular 2014-Sep-19 418kb
150 Minutes of Meeting 2014-Sep-08 22kb
151 Database of Fixed Dose Combinations (FDC's) Permitted for Manufacture for Sale in the Country 2014-Sep-05 574kb
152 Seventh Meeting of the Expert Committee on 29.08.2014 to examine the matters related to the approval of the safety and efficacy of Fixed Dose Combinations(FDC's) permitted for manufacture for sale in the country without due approval from office of DCG(I) 2014-Aug-29 262kb
153 Sixth Meeting of the Expert Committee on 27.08.2014 to examine the matters related to the approval of the safety and efficacy of Fixed Dose Combinations(FDC's) permitted for manufacture for sale in the country without due approval from office of DCG(I) 2014-Aug-27 274kb
154 Postponement of the Seventh Expert Committee Meeting from 29.08.2014 to 05.09.2014 to examine the matters related to the approval of the safety and efficacy of Fixed Dose Combinations(FDC's) permitted for manufacture for sale in the country without due approval from office of DCG(I) 2014-Aug-22 376kb
155 Specification and Criteria for Acceptance for test performed on blood glucose test strip and analyzer based glucose reagents 2014-Aug-07 359kb
156 Clarification on Form-29 for the Manufacture of Clinical Trial Material 2014-Jul-25 128kb
157 Use of antibiotcs for Treatment of food producing animals and in animal feed 2014-Jun-06 286kb
158 Approval of the safety and efficacy of FDC permitted for manufacture for sale in the country without due approval form office of DCG(I) 2014-Jun-05 167kb
159 Fourth Meeting of the Expert Committee on 11.06.2014 to Examine the Matters Related to Approval of the safety and efficacy of FDC Permitted 2014-May-26 132kb
160 Manufacture for sale in the country without due approval from office of DCG(I) 2014-May-26 174kb
161 Third Meeting of the Expert Committee on 04.06.2014 to examine the matters related to approval of the safety and efficacy of FDC permitted for manufacture for sale in the country without due approval from office of DCG(I) 2014-May-26 170kb
162 Second Meeting of the Expert Committee on 23.04.2014 to examine the matters related to the approval of the safety and efficacy of Fixed Dose Combinations(FDC's) permitted for manufacture for sale in the country without due approval from office of DCG(I) 2014-Apr-04 668kb
163 Approval of the safety and efficacy of FDCs 2014-Mar-28 311kb
164 Restriction on use of formulations of Tramadol, Tapentadol as well as FDCs containing Tramadol 2014-Feb-14 138kb
165 Cancellation of Permission of FDC of Olmesartan Medoxomil + Amlodipine + Hydrochlorothiazide tablets 2014-Feb-07 441kb
166 Circular Regarding Approval of Safety and Efficacy Marketed in the Country of FDC's Without Approval from DCG(I) 2014-Feb-03 322KB
167 Bringing details about Drug Import alert/restrictions imposed by regulatory authorities abroad 2014-Jan-28 504KB
168 Grant of Permission to Manufacture and Market FDC of Cefixime 200mg 2013-Nov-11 184KB
169 Grant of Permission to Manufacture and Market Certain FDC 2013-Nov-05 154kb
170 Grant of Permission to Manufacture and Market FDC of Ofloxacin 200mg 2013-Oct-17 147KB
171 Approval of the safety and efficacy of Fixed Dose Combinations(FDCs) permitted for manufacture for sale in country without due approval from office of DCG(I) 2013-Sep-02 866kb
172 Furnishing of information in respect of financial support, fees, honorarium, payments in kind etc to be paid to the investigator as per contract entered into by the sponsor with the investigator/ insititution in clinical trials 2013-Aug-30 310kb
173 Approval of the safety and efficacy of FDCs permitted for manufacture for sale in country without due approval form office of DCG(I) 2013-Aug-26 567kb
174 Circular dated 05.07.2013 regarding approval of the safety and efficacy of Fixed Dose Combinations (FDCs) permitted for manufacture for sale in the country without due approval from office of DCG(I) 2013-Jul-05 912kb
175 Circular regarding re-labeling/re-printing of revised prices as per NPPA's 2013-Jun-26 499kb
176 Circular regarding drug import alert/ restrictions imposed by regulatory authorities abroad 2013-Jun-26 343kb
177 Sub -rule 3A of Rule 97 of drugs and cosmetics rules 1945 regarding withdrawal period 2013-May-23 244kb
178 Letter regarding safety and efficacy of FDCs permitted by State Licensing Authority without prior approval from DCG(I) 2013-Mar-21 288kb
179 Letter Approval of the safety and efficacy of Fixed Dose Combinations Permitted for manufacture for sale in the country without due approval form office of DCG(I) 2013-Jan-15 681kb
180 Letter To establish the safety and efficacy of the FDC of Flupenthixol+Melitracen on Indian population. 2013-Jan-10 400kb
181 Letter Cancellation of permission/License in case an applicant/manufacturer fails to launch their product within a period of six month from obtaining the permission/license from CDSCO 2013-Jan-10 365kb
182 General Information on antibiotics and antibiotic resistance. 2012-Dec-10 84kb
183 Order issued to CDSCO Zonal Offices on Special drive for assuring the quality of medicines. 2012-Dec-05 384kb
184 Letter on Important safety label changes to cholesterol lowering stating drug. 2012-Nov-06 1,030kb
185 Order regarding “Box Warning” on label/package insert of formulations containing Nimesulide. 2012-Apr-14 280kb
186 Clarification regarding Limiting of Acetaminophen (Paracetamol) in prescription combination products. 2012-Apr-04 329kb
187 Circular regarding import of Cosmetic 2011-Nov-16 148kb
188 Cosmetic NOC 2011-Nov-16 144kb
189 Letter regarding Limiting of Acetaminophen (Paracetamol) in Prescription Combination Products 2011-Sep-23 116kb
190 Letter regarding Phasing out of oral Single Drug Formulations of Artemisinin. 2011-Apr-25 110kb
191 Letter regarding Information for submission to Department related Parliament Standing Committee on H&FW 2011-Feb-03 62kb
192 Letter regarding Prohibition of manufacture and sale of Rosiglitazone. 2010-Nov-16 156kb
193 Letter regarding Suspension of import/manufacture of rosiglitazone in the country. 2010-Oct-07 101kb